Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: Systematic Review and Meta-analysis

American Journal of Kidney Diseases

Volumn 52, Issue 5, 2008, Pages 897-906

  Rozen Zvi, Benaya ^a   Gafter Gvili, Anat ^b   Paul, Mical ^b   Leibovici, Leonard ^b   Shpilberg, Ofer ^b   Gafter, Uzi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Anemia; chronic kidney disease; hemodialysis; hemoglobin; iron; meta analysis

Indexed keywords

ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SUCCINATE; FERROUS SULFATE; FERUMOXYTOL; HEMOGLOBIN; IRON; IRON DEXTRAN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIALYSIS; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TRANSPLANTATION; META ANALYSIS; PERITONEAL DIALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; DIETARY SUPPLEMENTS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY DISEASES;

EID: 54349090164     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.05.033     Document Type: Article

References (44)

1. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
2. Hsu C.Y., McCulloch C.E., and Curhan G.C. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13 (2002) 504-510
3. Levin A., Thompson C.R., Ethier J., et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34 (1999) 125-134
4. Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., and Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316 (1987) 73-78
5. Eschbach J.W., Abdulhadi M.H., Browne J.K., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111 (1989) 992-1000
6. Macdougall I.C., Hutton R.D., Cavill I., Coles G.A., and Williams J.D. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ 299 (1989) 157-158
7. Danielson B. R-HuEPO hyporesponsiveness-Who and why?. Nephrol Dial Transplant 10 suppl 2 (1995) S69-S73
8. Sunder-Plassmann G., and Horl W. Erythropoietin and iron. Clin Nephrol 47 (1997) 141-157
9. Van Wyck D.B., Stivelman J.C., Ruiz J., Kirlin L.F., Katz M.A., and Ogden D.A. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35 (1989) 712-716
10. Silverberg D.S., Iaina A., Peer G., et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27 (1996) 234-238
11. Fishbane S. Iron supplementation in renal anemia. Semin Nephrol 26 (2006) 319-324
12. Horl W.H. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 18 (2007) 382-393
13. Van Wyck D.B., Cavallo G., Spinowitz B.S., et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 36 (2000) 88-97
14. Walters B.A., and Van Wyck D.B. Benchmarking iron dextran sensitivity: Reactions requiring resuscitative medication in incident and prevalent patients. Nephrol Dial Transplant 20 (2005) 1438-1442
15. Zager R.A., Johnson A.C., and Hanson S.Y. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65 (2004) 2108-2112
16. Brewster U.C., and Perazella M.A. Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 17 (2004) 57-60
17. Zager R.A., Johnson A.C., Hanson S.Y., and Wasse H. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40 (2002) 90-103
18. Agarwal R., Vasavada N., Sachs N.G., and Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65 (2004) 2279-2289
19. National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendation for Anemia in Chronic Kidney Disease in Adults. Am J Kidney Dis 47 suppl 3 (2006) S11-S145
20. Locatelli F., Aljama P., Barany P., et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 suppl 2 (2004) Sii1-Sii47
21. Gillespie R.S., and Wolf F.M. Intravenous iron therapy in pediatric hemodialysis patients: A meta-analysis. Pediatr Nephrol 19 (2004) 662-666
22. Notebaert E., Chauny J.M., Albert M., Fortier S., Leblanc N., and Williamson D.R. Short-term benefits and risks of intravenous iron: A systematic review and meta-analysis. Transfusion 47 (2007) 1905-1918
23. In: Higgins J.P.T.G.S. (Ed). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (2005), Wiley, Chichester, UK
24. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis 39 suppl 1 (2002) S1-S266
25. Schulz K.F., Chalmers I., Hayes R.J., and Altman D.G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273 (1995) 408-412
26. Warady B.A., Kausz A., Lerner G., et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 19 (2004) 655-661
27. Allegra V., Mengozzi G., and Vasile A. Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron 57 (1991) 175-182
28. Li H., and Wang S.X. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif 26 (2008) 151-156
29. Fishbane S., Frei G.L., and Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26 (1995) 41-46
30. Macdougall I.C., Tucker B., Thompson J., Tomson C.R., Baker L.R., and Raine A.E. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50 (1996) 1694-1699
31. Michael B., Trout J.R., Horl W.H., Volinn W., Jorjensen N., and Dahl N.V. Effectiveness of continuous low-dose intravenous ferric gluconate therapy for maintaining Hb and decreasing epoetin requirement in hemodialysis patients. J Am Soc Nephrol 18 (2007) 289A (abstr)
32. Svara F., Sulkova S., Kvasnicka J., and Polakovic V. Iron supplementation during erythropoietin therapy in patients on hemodialysis. Vnitr Lek 42 (1996) 849-852
33. Charytan C., Qunibi W., and Bailie G.R. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100 (2005) c55-c62
34. Agarwal R., Rizkala A.R., Bastani B., Kaskas M.O., Leehey D.J., and Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26 (2006) 445-454
35. Aggarwal H.K., Nand N., Singh S., Singh M., Hemant, and Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 51 (2003) 170-174
36. Van Wyck D.B., Roppolo M., Martinez C.O., Mazey R.M., and McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68 (2005) 2846-2856
37. Spinowitz B.S., Besarab A., Bolton W.K., et al. Ferumoxytol as an intravenous iron replacement therapy in chronic kidney disease (CKD) patients not on dialysis-Evaluation of safety and efficacy in two phase III studies. J Am Soc Nephrol 17 (2006) 342A (abstr)
38. Stoves J., Inglis H., and Newstead C.G. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16 (2001) 967-974
39. Fishbane S. Iron management in nondialysis-dependent CKD. Am J Kidney Dis 49 (2007) 736-743
40. Kooistra M.P., Niemantsverdriet E.C., van Es A., Mol-Beermann N.M., Struyvenberg A., and Marx J.J. Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 13 (1998) 82-88
41. Agarwal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 69 (2006) 1259-1263
42. Bishu K., and Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 1 suppl 1 (2006) S19-S23
43. Zager R.A. Parenteral iron compounds: Potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol 1 suppl 1 (2006) S24-S31
44. Lenga I., Lok C., Marticorena R., Hunter J., Dacouris N., and Goldstein M. Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol 2 (2007) 688-693